Announcements Trials
Browse Landscape

Phase

Phase 1 1

Status

Withdrawn 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Head & Neck 1

Conditions

Myelodysplastic Syndromes 8Leukemia, Myeloid, Acute 7Leukemia, Myelomonocytic, Chronic 5Squamous Cell Carcinoma of Head and Neck 1Solid Tumor 1Melanoma 1Leukemia, Biphenotypic, Acute 1Leukemia 1Hematologic Diseases 1Cytopenia 1Carcinoma, Squamous Cell 1Anemia, Refractory, with Excess of Blasts 1

Interventions

Cisplatin 274pembrolizumab 229Radiotherapy 166Cetuximab 163Carboplatin 122Docetaxel 109Paclitaxel 94Fluorouracil 94Nivolumab 84Radiotherapy, Intensity-Modulated 78Magnetic Resonance Spectroscopy 39durvalumab 35Radiation 32Surgical Procedures, Operative 31Drug Therapy 30Radiosurgery 25Erlotinib Hydrochloride 25Biopsy 25Albumin-Bound Paclitaxel 24130-nm albumin-bound paclitaxel 24Taxes 23Platinum 22Specimen Handling 21tislelizumab 201,2-diaminocyclohexaneplatinum II citrate 20Cyclophosphamide 19Capecitabine 19tremelimumab 18Ipilimumab 18Gemcitabine 18

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Interventional × Squamous Cell Carcinoma of Head and Neck × cedazuridine × Clear all
NCT06357858 2024-07-03

ASTX727 and Nivolumab in Squamous Cell Carcinoma of the Head and Neck

Case Comprehensive Cancer Center

Phase 1 Withdrawn
Head & Neck

Squamous Cell Carcinoma of Head and Neck, Carcinoma, Squamous Cell

Data powered by HemOnc (CC BY 4.0) Colophon âš¡